

Advancing Leukemia Diagnosis and Treatment: WHO-Supported Laboratory Innovations in Africa- A Narrative Review

Emmanuel Ifeanyi Obeagu ^{1,2}

¹Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe; ²Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda

Correspondence: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe, Email emmanuelobeagu@yahoo.com

Abstract: Leukemia remains a major health challenge in Africa, where limited access to advanced diagnostic technologies often leads to delayed diagnosis and suboptimal treatment outcomes. This review explores the role of WHO-supported laboratory innovations in advancing leukemia diagnosis across the continent. It examines key technologies such as molecular diagnostics, flow cytometry, and cytogenetics, highlighting how these innovations have enhanced the accuracy and speed of leukemia detection in resource-limited settings. By facilitating early and precise diagnoses, these technologies are improving patient management and treatment outcomes. Despite the promising advancements, significant barriers to widespread implementation persist, including high costs, inadequate infrastructure, and a shortage of trained personnel. WHO's efforts to address these challenges through regional collaborations, technical assistance, and capacity-building initiatives are pivotal in overcoming these obstacles. The establishment of specialized diagnostic centers and the integration of advanced technologies into national healthcare systems are key strategies to expand access and improve leukemia care in Africa.

Keywords: leukemia diagnosis, WHO support, laboratory innovations, Africa, healthcare improvement

Introduction

Leukemia, a hematologic cancer that affects the blood and bone marrow, represents a major health challenge worldwide, including in Africa. It is a disease that, if diagnosed early, can be treated more effectively, leading to improved survival rates and quality of life for affected individuals. However, in many parts of Africa, leukemia diagnosis is often delayed or missed entirely due to inadequate healthcare infrastructure, lack of trained medical personnel, and limited access to advanced diagnostic technologies. These challenges are particularly pronounced in low-resource settings, where basic diagnostic tools may be unavailable or unaffordable. As a result, many African patients are diagnosed at advanced stages of the disease when treatment options are more limited, contributing to poor outcomes.¹⁻⁵ The World Health Organization (WHO) has long recognized the need to address these challenges and improve healthcare delivery in Africa. The organization has been instrumental in supporting laboratory innovations that enhance the diagnosis of leukemia and other cancers across the continent. WHO's efforts focus on increasing access to advanced diagnostic technologies, such as molecular testing, flow cytometry, and cytogenetic analysis, which have revolutionized leukemia diagnosis globally. These innovations not only help to identify the specific type of leukemia but also provide crucial information for personalized treatment planning, which can significantly improve survival rates. By improving diagnostic accuracy and speed, WHO-supported laboratory innovations have the potential to change the landscape of leukemia care in Africa.⁶⁻⁸ In recent years, WHO has collaborated with African governments, international organizations, and local health agencies to introduce and scale these laboratory innovations. The goal is to bridge the diagnostic gap between Africa and more developed regions, where cutting-edge technologies are more widely available. While significant strides

have been made, there remains a large gap in access to these innovations across the continent, especially in rural and underserved regions. As a result, this review will examine the key laboratory innovations in leukemia diagnosis that WHO has supported, assess their impact on healthcare systems in Africa, and explore the challenges that continue to hinder their widespread implementation.⁹

One of the most notable advancements in leukemia diagnosis is the introduction of molecular diagnostic technologies, including polymerase chain reaction (PCR) and next-generation sequencing (NGS). These technologies allow for the detection of specific genetic mutations and chromosomal abnormalities that are characteristic of different types of leukemia. For example, the Philadelphia chromosome, a genetic abnormality often associated with chronic myelogenous leukemia (CML), can be detected using molecular diagnostics. The ability to identify such mutations at an early stage helps doctors make more informed treatment decisions, improving patient outcomes. WHO has played a critical role in introducing these technologies in select African hospitals and laboratories, where they are now being used to provide more accurate and timely leukemia diagnoses.^{10–12} Flow cytometry, another important diagnostic technology, has also been introduced with WHO support. This technology enables the analysis of cells based on their size, complexity, and surface markers, allowing clinicians to differentiate between various types of leukemia. Flow cytometry has proven invaluable in diagnosing acute leukemia, as it helps to identify the presence of abnormal cells and assess the disease's progression. WHO has provided technical support to healthcare facilities in Africa, equipping them with flow cytometers and training laboratory technicians to use them effectively. While flow cytometry is not yet universally available across the continent, its adoption in certain regions has led to better diagnosis and more targeted treatment for leukemia patients.¹³ Cytogenetic testing, which involves the study of chromosomes in leukemia cells, is another diagnostic tool that has been supported by WHO in Africa. This technique helps to identify chromosomal abnormalities such as translocations, deletions, and duplications, which can provide valuable insight into the type of leukemia a patient has. For example, the detection of the BCR-ABL fusion gene in CML patients is critical for determining the appropriate treatment. Although cytogenetic testing requires significant infrastructure and resources, WHO has helped establish regional cytogenetic laboratories in Africa, making this important diagnostic tool more accessible to patients in these areas. The impact of cytogenetics on leukemia diagnosis in Africa has been profound, enabling earlier and more accurate diagnoses that can guide treatment decisions.^{14–17}

Aim

The aim of this review is to explore and analyze the impact of World Health Organization (WHO)-supported laboratory innovations in improving leukemia diagnosis across Africa.

Justification of the Review

WHO-supported laboratory innovations have been instrumental in bridging the diagnostic divide. These initiatives include the introduction of cost-effective diagnostic tools, training programs for laboratory personnel, and the implementation of digital pathology and telemedicine solutions. Documenting these advancements provides valuable insights into how global health organizations are addressing diagnostic inequities and demonstrates the potential of these innovations to transform leukemia care in resource-limited settings. Moreover, the review serves as a platform for knowledge transfer, consolidating information on diagnostic advancements and the challenges faced in their implementation. This resource can guide healthcare professionals, policymakers, and researchers in adopting best practices, fostering collaboration, and tailoring solutions to the unique needs of African populations. Additionally, the review emphasizes the importance of equitable healthcare delivery. Inequities in diagnostic access and treatment disproportionately affect leukemia patients in Africa, particularly those in rural and underserved areas.^{1–4} By advocating for sustained investment in laboratory infrastructure and capacity building, this review aligns with global health goals to reduce disparities and improve health outcomes for all. Finally, the review aims to inspire further research and innovation by identifying gaps in current practices. Highlighting the challenges faced in implementing WHO-supported initiatives can stimulate new approaches and foster partnerships that prioritize sustainability and long-term impact.

Review Methodology

This narrative review was designed to provide a comprehensive exploration of WHO-supported laboratory innovations in leukemia diagnosis across Africa. To achieve this objective, a systematic yet flexible approach was adopted to gather, analyze, and synthesize information from diverse sources. The search for relevant data began with a thorough exploration of academic databases, including PubMed, Google Scholar, Scopus, and the WHO Global Health Observatory. These platforms were selected for their extensive coverage of peer-reviewed literature and public health data. In addition to these, official WHO reports, cancer registry data from African countries, and other gray literature sources were included to capture recent advancements and region-specific details. The timeframe for the search spanned from 2010 to 2024 to focus on contemporary innovations and trends in leukemia diagnostics. To refine the search, a set of keywords and phrases was employed, such as “leukemia diagnosis in Africa”, “WHO laboratory innovations”, “hematological malignancies”, and “cancer diagnostics in low-resource settings”. Boolean operators were used to combine these terms effectively, while filters were applied to exclude unrelated results and focus on English-language publications.

The inclusion and exclusion criteria were clearly defined to ensure the relevance and quality of the data gathered. Studies and reports focusing on leukemia diagnosis in Africa, particularly those highlighting WHO-supported initiatives, were included. Conversely, articles outside the African context, those lacking methodological rigor, and those unrelated to leukemia or laboratory diagnostics were excluded. The quality of the included studies was assessed using a standardized checklist tailored for narrative reviews. Factors such as methodological clarity, robustness of findings, relevance to the review’s objectives, and contextual applicability to African healthcare settings were evaluated to ensure reliability.

Laboratory Innovations in Leukemia Diagnosis

Leukemia, a diverse group of hematologic cancers, requires accurate and timely diagnosis for optimal patient management. Over the past few decades, laboratory innovations have played a pivotal role in enhancing the diagnosis of leukemia, improving prognostic accuracy, and guiding treatment decisions. These advancements have revolutionized leukemia care, providing a clearer understanding of the disease at a molecular level and enabling clinicians to tailor therapies to individual patients’ needs. In regions like Africa, where healthcare infrastructure often faces significant challenges, the introduction of these technologies is particularly important in overcoming diagnostic barriers and improving patient outcomes.^{18–20}

Molecular Diagnostics

One of the most significant laboratory innovations in leukemia diagnosis is the use of molecular diagnostic technologies. Techniques such as PCR, quantitative PCR, and NGS have enabled the detection of specific genetic mutations, chromosomal abnormalities, and gene rearrangements that are hallmark features of various leukemia subtypes. For example, the Philadelphia chromosome, a genetic abnormality involving a translocation between chromosomes 9 and 22, is a characteristic of CML. Identifying this abnormality early through molecular diagnostics is crucial for prognosis and for determining the appropriate treatment, such as targeted therapies with tyrosine kinase inhibitors. PCR techniques, which amplify and detect genetic material, provide an efficient and sensitive method for diagnosing specific mutations associated with leukemia. In African countries, where leukemia diagnosis has traditionally been based on morphology and clinical presentation, the introduction of molecular diagnostic techniques has brought about a paradigm shift. WHO-supported initiatives have facilitated the adoption of molecular diagnostics in selected healthcare facilities across Africa, contributing to more precise and timely diagnosis. The accessibility of these advanced tools can be life-saving, as early detection of mutations like the Philadelphia chromosome allows for personalized treatment options, significantly improving patient outcomes.^{21,22}

Flow Cytometry

Flow cytometry is another critical laboratory innovation in leukemia diagnosis. This technique involves analyzing cells based on their size, complexity, and the presence of specific surface markers. Flow cytometry is particularly useful for diagnosing hematologic cancers like leukemia, as it enables the identification of abnormal cells that may be present in the

blood or bone marrow. Leukemic cells often exhibit unique surface markers that distinguish them from normal cells, and flow cytometry can rapidly identify these markers, providing critical diagnostic information. In the context of leukemia, flow cytometry can help differentiate between various subtypes of acute leukemia, such as ALL and AML, based on the specific antigens expressed on the surface of malignant cells. Additionally, flow cytometry plays a crucial role in monitoring minimal residual disease (MRD) after treatment, enabling clinicians to assess the effectiveness of therapy and predict the risk of relapse. WHO's support for flow cytometry in African countries has led to its adoption in key diagnostic centers, where it is used to enhance the accuracy of leukemia diagnoses, even in resource-limited settings. By enabling the identification of specific leukemia subtypes, flow cytometry improves the overall quality of care and guides personalized treatment strategies.^{23–27}

Cytogenetic Analysis

Cytogenetic analysis, which involves the study of chromosomal changes in leukemia cells, is another essential tool in leukemia diagnosis. This technique can detect structural chromosomal abnormalities such as translocations, deletions, and duplications, which are characteristic of different leukemia types. For instance, the detection of the BCR-ABL fusion gene, commonly seen in CML, provides critical diagnostic and prognostic information. Similarly, the identification of other chromosomal abnormalities, such as mutations in the FLT3 gene in AML, can help guide treatment decisions. Cytogenetics plays a vital role in determining the prognosis of leukemia patients, as certain chromosomal abnormalities are associated with a better or worse outlook. WHO has facilitated the establishment of regional cytogenetics laboratories in several African countries, making this technology more accessible to patients in these regions. The ability to detect chromosomal abnormalities early in the diagnostic process allows for more accurate prognosis and the development of tailored treatment plans, improving overall patient survival.^{28–31}

Next-Generation Sequencing (NGS)

Next-generation sequencing (NGS) represents the cutting edge of molecular diagnostic technology. This high-throughput method allows for the comprehensive analysis of an individual's genetic makeup, enabling the detection of mutations, gene fusions, and epigenetic changes associated with leukemia. NGS has the advantage of being able to sequence multiple genes simultaneously, providing a broader view of the genetic alterations present in a patient's leukemia cells. This comprehensive approach allows for the identification of mutations that may not be detectable through other methods, ensuring a more complete diagnostic picture. NGS is especially useful in identifying rare mutations or those that may not have been previously associated with leukemia, which could open the door to new treatment options. WHO has been instrumental in introducing NGS technologies to some African countries, although the cost and complexity of the technology remain a challenge. Still, with the ongoing advancement of sequencing technologies and the increasing availability of lower-cost alternatives, NGS has the potential to become more widely accessible, offering a game-changing tool in the diagnosis and treatment of leukemia.^{11,30,32–35}

Laboratory Capacity Building and Training

In order to effectively implement these laboratory innovations, there is a critical need for capacity building and training. Many African healthcare systems face a shortage of trained personnel who can operate sophisticated diagnostic equipment such as flow cytometers and NGS platforms. WHO's efforts in training laboratory technicians and clinicians are crucial to ensuring the successful integration of these technologies into clinical practice. Specialized training programs and workshops have been organized to enhance the skills of laboratory professionals, ensuring that they are equipped to handle complex diagnostic tools. The creation of regional centers of excellence in laboratory diagnostics, supported by WHO, has also contributed to building capacity in Africa. These centers not only provide diagnostic services but also serve as hubs for training and knowledge-sharing among healthcare professionals. By improving the technical expertise of healthcare workers, WHO is helping to ensure that the latest laboratory innovations are implemented effectively and sustainably across the continent.^{36–39}

Overcoming Barriers to Implementation

Despite the significant advances in laboratory technology, several barriers remain to the widespread implementation of these innovations in Africa. The high costs associated with advanced diagnostic tools such as PCR, NGS, and flow cytometry pose a major challenge. While WHO's support helps to alleviate some of these financial burdens through donations and technical assistance, many African countries still struggle to secure the necessary funding for these technologies. Additionally, the lack of reliable infrastructure, such as stable electricity and internet connectivity, can hinder the functionality of advanced diagnostic equipment in remote areas. To overcome these barriers, WHO is working with African governments and international partners to improve healthcare infrastructure and secure sustainable funding for leukemia diagnostic initiatives. Collaboration between public and private sectors, as well as international organizations, will be key to ensuring that laboratory innovations are more accessible to underserved populations across Africa. Through these collaborative efforts, the gap in leukemia diagnosis can be narrowed, ultimately improving survival rates and quality of life for patients across the continent.^{40–43}

Challenges in Expanding Diagnostic Access for Leukemia in Africa

Expanding access to leukemia diagnostics in Africa faces a range of challenges, many of which are deeply rooted in the continent's healthcare infrastructure, socio-economic conditions, and regional disparities in medical resources. While advancements in diagnostic technologies, such as molecular diagnostics, flow cytometry, and next-generation sequencing (NGS), have transformed leukemia diagnosis globally, the implementation of these technologies in Africa is hindered by several obstacles. Addressing these challenges is crucial to improving the overall diagnostic capacity for leukemia and ensuring timely and accurate treatment for patients across the continent.^{44–46}

Limited Healthcare Infrastructure

One of the primary challenges in expanding diagnostic access for leukemia is the limited healthcare infrastructure in many African countries. Inadequate hospital facilities, insufficient laboratory equipment, and the lack of a robust supply chain for reagents and consumables significantly impede the ability of healthcare providers to adopt advanced diagnostic technologies. In rural and remote areas, access to even basic diagnostic services is often constrained, making the introduction of sophisticated tools such as flow cytometers and NGS platforms particularly difficult. Without proper infrastructure, diagnostic laboratories are ill-equipped to manage the demands of modern leukemia diagnostics. Additionally, power outages and inconsistent access to electricity further complicate the operation of high-tech diagnostic equipment. These challenges result in delays in diagnosis, potential errors in test results, and increased costs associated with maintenance and equipment downtime. WHO's support in infrastructure development is vital, but efforts must be expanded to ensure that diagnostic equipment is adequately supported by the necessary infrastructure, including reliable power sources and transportation networks for reagents and samples.^{47–50}

High Costs of Diagnostic Technologies

The high costs associated with advanced diagnostic tools are another significant barrier to widespread access in Africa. Technologies such as next-generation sequencing, polymerase chain reaction (PCR), and flow cytometry are expensive both in terms of initial setup and ongoing operational costs. While these technologies can significantly improve the accuracy of leukemia diagnosis, the financial burden they place on healthcare systems, especially in low-resource settings, remains a major challenge. This issue is exacerbated by the limited healthcare budgets in many African countries, which often prioritize other pressing health issues over cancer diagnostics. For many African countries, the adoption of molecular diagnostics and NGS technologies requires substantial investment in both equipment and the training of specialized personnel. Even with WHO's support, the upfront costs of setting up molecular diagnostic laboratories can be prohibitively high. Furthermore, the ongoing costs of reagents, consumables, and maintenance of sophisticated diagnostic equipment can strain already limited healthcare budgets, particularly in public health sectors. As a result, many healthcare facilities are unable to afford these advanced diagnostic tools, leading to a reliance on outdated, less accurate diagnostic methods.⁵¹

Shortage of Skilled Personnel

The shortage of trained personnel capable of operating advanced diagnostic technologies is a key challenge in expanding access to leukemia diagnosis in Africa. Specialized training in molecular diagnostics, flow cytometry, and other leukemia-related diagnostic techniques requires investment in human capital. However, many African countries face a shortage of trained laboratory technicians and hematologists, limiting the capacity to fully implement these technologies. Additionally, specialized training programs are often scarce, and healthcare workers may have limited opportunities to gain hands-on experience with cutting-edge diagnostic equipment. WHO has supported the establishment of regional training centers and capacity-building programs to address this issue, but the demand for trained personnel far exceeds the supply. In many African countries, laboratory staff may be overworked, underpaid, and lack the resources to stay updated on the latest advancements in leukemia diagnostics. As a result, even where diagnostic technologies are available, there may be insufficient expertise to utilize them effectively. Overcoming this challenge requires long-term investment in healthcare education, training programs, and continuing professional development for laboratory professionals across the continent.^{52,53}

Regional Disparities in Access to Diagnostics

There are significant regional disparities in access to leukemia diagnostics across Africa. Urban areas, particularly in countries with more developed healthcare systems, tend to have better access to advanced diagnostic technologies. In contrast, rural and remote areas are often underserved, with limited access to even basic healthcare services. These disparities are further exacerbated by differences in socio-economic status, education levels, and regional health policies. As a result, patients living in rural or underserved areas are less likely to receive timely and accurate diagnoses, leading to delayed treatment and worse outcomes. The concentration of advanced diagnostic technologies in large cities creates an uneven distribution of healthcare resources, making it difficult for patients in rural areas to benefit from innovations in leukemia diagnostics. Furthermore, patients in these regions may face additional barriers such as transportation costs, lack of awareness about leukemia symptoms, and cultural barriers that prevent them from seeking timely medical attention. Expanding diagnostic access in these underserved areas requires targeted interventions, including mobile diagnostic units, telemedicine, and the establishment of satellite clinics equipped with basic diagnostic tools.⁵⁴

Limited Public Awareness and Education

Limited public awareness and education about leukemia and its diagnostic options also pose challenges in expanding access to early diagnosis. Many individuals in Africa may not be aware of the symptoms of leukemia or may mistakenly attribute them to other, more common illnesses. The lack of awareness about the importance of early diagnosis often leads to delays in seeking medical attention, reducing the likelihood of successful treatment outcomes. Additionally, misconceptions and stigma surrounding cancer may prevent patients from accessing care, especially in communities with strong cultural or religious beliefs. Education campaigns to raise awareness about leukemia and its diagnostic processes are essential for encouraging early detection and treatment. WHO and other international organizations have made strides in improving public health education, but there is still much work to be done. Expanding public awareness efforts and ensuring that accurate information about leukemia symptoms, diagnosis, and treatment is available in local languages can help reduce stigma and promote earlier diagnosis, particularly in rural and remote areas.^{55,56}

Policy and Governance Challenges

Another challenge in expanding access to leukemia diagnostics is the lack of robust health policies and governance structures in some African countries. While some governments have developed national cancer control plans, many lack comprehensive strategies for addressing leukemia specifically. The absence of clear policy frameworks, coordinated efforts between government bodies, and funding mechanisms can hinder progress in expanding diagnostic access. Moreover, the integration of leukemia diagnostics into broader cancer care programs often lacks prioritization, leading to fragmented services that are not widely available or accessible. WHO has worked with African governments to develop national cancer control programs and policies, but the implementation of these policies often faces hurdles such

as political instability, competing health priorities, and limited funding. A concerted effort to strengthen health governance, improve policy frameworks, and ensure political will is crucial to overcoming these systemic barriers. By prioritizing leukemia diagnostics within broader healthcare policies, African governments can ensure that appropriate resources are allocated to improve diagnostic access and treatment outcomes.^{57,58}

WHO's Role in Supporting Laboratory Innovations for Leukemia Diagnosis in Africa

The World Health Organization (WHO) has played a pivotal role in enhancing laboratory diagnostics for leukemia across Africa, addressing the growing burden of cancer on the continent through the introduction of innovative technologies and comprehensive support initiatives. As part of its mission to improve health outcomes globally, WHO recognizes the importance of timely and accurate leukemia diagnosis in ensuring effective treatment and better survival rates. In the context of Africa, where healthcare infrastructure and resources are often limited, WHO's involvement in fostering laboratory innovations is critical to overcoming diagnostic barriers and providing equitable access to quality care.⁵⁹

Promoting Capacity Building and Training

WHO has been instrumental in promoting capacity building for laboratory professionals across Africa. The organization has supported the establishment of regional training programs and workshops to equip laboratory technicians, hematologists, and other healthcare professionals with the necessary skills to operate advanced diagnostic tools such as flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). By facilitating hands-on training and education, WHO ensures that healthcare workers across the continent can effectively utilize these technologies to diagnose leukemia in its early stages, increasing the chances of successful treatment outcomes. Additionally, WHO has partnered with African countries to develop standardized training curricula for leukemia diagnostics. This initiative aims to address the skill gap in hematology laboratories and to ensure that laboratory professionals are equipped with up-to-date knowledge on emerging diagnostic methodologies. WHO's training programs also focus on fostering continuous professional development, ensuring that healthcare workers stay informed about the latest innovations in leukemia diagnosis and treatment.^{60,61}

Supporting the Introduction of Advanced Diagnostic Technologies

Another essential role WHO plays is in supporting the introduction and adoption of advanced diagnostic technologies in African laboratories. The organization provides technical assistance and guidance to healthcare systems on how to integrate cutting-edge diagnostic tools into their existing infrastructures. WHO's support extends to the procurement and installation of sophisticated diagnostic equipment, ensuring that healthcare facilities in Africa are equipped to diagnose leukemia accurately. WHO also helps in creating frameworks for the maintenance, calibration, and optimal use of diagnostic machines, ensuring sustainability and effectiveness. While the initial investment in these technologies can be high, WHO collaborates with international donors, governments, and non-governmental organizations to mitigate the financial burden on local healthcare systems, making advanced diagnostic methods more accessible. Furthermore, WHO advocates for the inclusion of leukemia diagnostic tools in national cancer control programs, ensuring that diagnostic capacity is integrated into broader healthcare planning.⁶²

Strengthening Healthcare Networks and Collaboration

WHO fosters collaboration between national health ministries, academic institutions, and international partners to enhance leukemia diagnostic capabilities. By building networks of specialized laboratories and creating regional centers of excellence, WHO helps ensure that the latest diagnostic innovations are shared and disseminated across African nations. These collaborations also support the establishment of referral networks, where patients in rural or underserved areas can be referred to specialized centers with advanced diagnostic capabilities. In addition to strengthening regional networks, WHO actively works to harmonize diagnostic protocols across Africa. By standardizing diagnostic approaches and ensuring that laboratories adhere to international best practices, WHO helps to increase the reliability and accuracy of leukemia diagnosis throughout the continent. Standardization also aids in data collection and surveillance, providing valuable insights into the prevalence and trends of leukemia, which can inform future research and health policy decisions.^{63,64}

Enhancing Access to Diagnostic Reagents and Supplies

Access to the necessary reagents and diagnostic supplies is another area where WHO's support is vital. In many African countries, the availability of critical diagnostic materials such as antibodies, reagents, and consumables can be inconsistent, often due to supply chain disruptions or financial constraints. WHO works with local health systems to establish reliable supply chains and procurement strategies, ensuring that laboratories are adequately stocked with the necessary materials for leukemia diagnosis. Moreover, WHO advocates for the integration of leukemia diagnostic tools and reagents into the essential medicines lists of African countries, promoting policies that prioritize cancer diagnostics as part of national healthcare priorities. This support helps reduce the barriers to accessing diagnostic services, ensuring that healthcare providers are well-equipped to diagnose leukemia when cases arise.⁶⁵

Facilitating Research and Development

WHO also plays a crucial role in fostering research and development (R&D) to improve leukemia diagnostic techniques in Africa. By supporting clinical research initiatives and facilitating collaborations between African research institutions and global partners, WHO contributes to the development of new diagnostic tests and biomarkers that can enhance the early detection of leukemia in diverse populations. Research supported by WHO focuses on tailoring diagnostic tools to the unique genetic and environmental factors found in African populations, ensuring that diagnostic innovations are culturally relevant and effective. Additionally, WHO's involvement in clinical trials and pilot programs enables the testing of novel diagnostic approaches in real-world settings, providing valuable data on their effectiveness and feasibility in resource-limited environments. This research-driven approach ensures that Africa can benefit from cutting-edge diagnostic innovations while simultaneously addressing the continent's unique healthcare challenges.⁵¹

Policy Advocacy and Health System Strengthening

WHO's advocacy efforts are crucial in influencing national policies on leukemia diagnostics and cancer care in Africa. By working with governments and health ministries, WHO helps integrate leukemia diagnosis into national cancer control plans and health agendas. This policy support is essential for ensuring that leukemia diagnostics receive the necessary attention and funding within the broader healthcare system. WHO also provides technical assistance to African governments in strengthening their health systems to improve access to diagnostics. By helping countries build sustainable healthcare infrastructures, WHO ensures that advancements in leukemia diagnosis are not short-term fixes but are integrated into long-term strategies for cancer care. This systemic approach is essential for overcoming the challenges of diagnostic accessibility and ensuring that diagnostic tools and treatments reach those who need them most.^{1,64}

Impact of Innovations on Patient Outcomes in Leukemia Diagnosis in Africa

Innovations in leukemia diagnosis have had a profound impact on patient outcomes in Africa, offering significant improvements in early detection, treatment efficacy, and overall survival rates. By enhancing the accuracy and timeliness of diagnoses, these innovations have allowed healthcare providers to detect leukemia at earlier, more treatable stages. The availability of advanced diagnostic technologies, including flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS), has revolutionized how leukemia is diagnosed, providing critical insights into the disease's molecular profile and enabling more personalized treatment plans. This section explores how these innovations have directly impacted patient outcomes in the African context.^{66,67}

Early Detection and Improved Prognosis

One of the most significant impacts of diagnostic innovations on patient outcomes is the ability to detect leukemia at earlier stages. Traditionally, leukemia diagnoses in Africa were often delayed due to limited access to advanced diagnostic tools, leading to a high number of patients presenting with advanced stages of the disease. Innovations in laboratory diagnostics, such as PCR and flow cytometry, allow for more accurate and earlier detection of leukemia, which is crucial for improving the prognosis. Early detection increases the likelihood of patients responding positively to treatment, reduces the need for aggressive interventions, and enhances overall survival rates. For example, molecular techniques such as PCR can identify

specific genetic mutations and abnormalities that are indicative of leukemia, even in its early stages. These techniques enable healthcare providers to diagnose leukemia before it progresses to an advanced stage, offering patients a better chance of successful treatment outcomes. The ability to detect leukemia early also helps reduce the number of unnecessary treatments for other diseases, reducing both the physical and emotional burden on patients.⁶⁸

Personalized and Targeted Treatment Plans

Innovations in leukemia diagnostics have also led to more personalized and targeted treatment strategies, which have had a significant impact on patient outcomes. Through advanced diagnostic techniques such as NGS and immunophenotyping, clinicians are able to determine the specific subtype and genetic makeup of leukemia in individual patients. This detailed molecular information allows for the development of tailored treatment plans that are more effective in targeting the unique characteristics of each patient's leukemia. Personalized treatment approaches, including targeted therapies and precision medicine, are often more effective than traditional one-size-fits-all treatments. By identifying the specific mutations and molecular pathways involved in a patient's leukemia, clinicians can select the most appropriate drugs, reducing the risk of adverse reactions and improving the likelihood of remission. In Africa, where access to healthcare resources can be limited, these innovations maximize the use of available therapies, ensuring that patients receive the most appropriate and effective treatment based on their specific diagnostic profile.⁶⁹

Reduced Treatment Toxicity and Improved Quality of Life

The integration of advanced diagnostics in leukemia treatment also helps to minimize the toxicity associated with conventional chemotherapy. Traditional treatments for leukemia often involve aggressive chemotherapy regimens that can have severe side effects, including organ damage, infection, and a significant reduction in the patient's quality of life. By using precise diagnostic information to identify the most effective treatment options, healthcare providers can reduce the use of harsh treatments and tailor interventions to the patient's needs. For example, molecular testing may reveal that a patient's leukemia is resistant to certain chemotherapy drugs, allowing clinicians to avoid using those drugs and potentially reduce side effects. Additionally, by identifying specific molecular targets, clinicians can offer more effective targeted therapies that cause fewer side effects and improve the patient's overall quality of life. This is particularly important in resource-limited settings, where supportive care services may be less accessible, and reducing the toxic effects of treatment can significantly enhance patient well-being.⁷⁰

Improved Access to Treatment and Better Survival Rates

Innovations in leukemia diagnostics, particularly through the implementation of molecular techniques and the establishment of regional diagnostic hubs, have improved access to timely and accurate diagnosis across Africa. In the past, many patients in rural and remote areas faced significant challenges in obtaining a proper diagnosis due to the lack of specialized laboratories and diagnostic technologies. With the support of international organizations like WHO and regional collaborations, diagnostic innovations are increasingly accessible, even in underserved regions. As access to accurate diagnostics improves, more patients are being diagnosed earlier and are receiving treatment sooner. This shift has led to better survival rates and outcomes for leukemia patients, as early-stage leukemia is often more responsive to treatment. In regions where diagnostic innovations are being implemented, survival rates for both childhood and adult leukemia patients have seen improvements, demonstrating the positive impact of accessible, high-quality diagnostics on patient outcomes.⁷¹

Data-Driven Decision Making and Long-Term Monitoring

The innovations in leukemia diagnostics have also enabled better data collection, which is essential for ongoing patient management and long-term monitoring. By using technologies such as NGS and flow cytometry, clinicians can generate detailed molecular profiles of leukemia cases, allowing for more accurate monitoring of disease progression and treatment response. This data-driven approach helps healthcare providers make more informed decisions regarding the adjustment of treatment plans and the detection of any recurrence or relapse of the disease. Long-term monitoring through advanced diagnostics is particularly important in the management of chronic leukemia types, such as chronic

lymphocytic leukemia (CLL), where patients require continuous follow-up to ensure that the disease remains under control. Innovations in diagnostics enable healthcare systems to track these patients more effectively, leading to better management of their condition and improved long-term outcomes. Furthermore, the data collected from diagnostic innovations can contribute to broader research initiatives, providing insights into the epidemiology of leukemia in Africa and helping to inform future healthcare policies and strategies.⁷²

Overcoming Healthcare Inequities

Finally, the impact of diagnostic innovations on patient outcomes extends to the broader challenge of addressing healthcare inequities in Africa. By introducing advanced diagnostic technologies, WHO and other international organizations have made significant strides in reducing the gap in leukemia care between urban and rural areas. Regional diagnostic hubs, mobile diagnostic units, and telemedicine initiatives have made it possible for patients in remote areas to access high-quality leukemia diagnostics, ensuring that more individuals have the opportunity to receive an accurate diagnosis and appropriate treatment. This reduction in healthcare inequities is critical for improving overall health outcomes in Africa. By ensuring that diagnostic innovations reach all regions, including underserved rural areas, the gap in leukemia survival rates between different socio-economic groups can be narrowed. Moreover, providing equitable access to diagnostics enhances trust in the healthcare system and encourages early detection, which ultimately benefits patients and healthcare systems alike.⁷³

Expanding Access to Diagnostic Innovations in Leukemia in Africa

Expanding access to diagnostic innovations for leukemia in Africa is a critical step toward improving healthcare outcomes and reducing the mortality rates associated with the disease. While significant progress has been made in the development and implementation of advanced diagnostic technologies, there remains a vast disparity in access to these tools across the continent. Expanding access to such innovations is essential for ensuring early and accurate diagnosis, which in turn facilitates timely and effective treatment. This section explores the key strategies and initiatives necessary to overcome barriers and ensure that diagnostic innovations reach all corners of Africa, particularly underserved and resource-limited regions.⁷⁴

Overcoming Infrastructure and Resource Constraints

One of the primary challenges in expanding access to leukemia diagnostic innovations in Africa is the limited healthcare infrastructure and resources available, particularly in rural and remote areas. Many healthcare facilities across the continent are not equipped with the necessary infrastructure to support advanced diagnostic technologies like flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). To address this, it is essential to invest in upgrading laboratory facilities and providing the necessary equipment to hospitals and clinics, particularly those in rural or underserved areas. In many African countries, centralized diagnostic laboratories in major cities are often overwhelmed with cases, leading to delays in diagnosis and treatment. To mitigate this, decentralizing diagnostic services and setting up regional diagnostic hubs can significantly improve access. These hubs can serve as referral centers where patients from surrounding areas can access specialized leukemia diagnostic tools, avoiding the need for patients to travel long distances to major cities. Expanding the reach of these diagnostic centers is critical for ensuring that all patients, regardless of their geographic location, have access to timely and accurate diagnoses.⁷⁵

Capacity Building and Training Healthcare Workers

Access to diagnostic innovations also depends on the availability of skilled healthcare workers capable of operating and interpreting the results of advanced diagnostic tools. In many parts of Africa, there is a shortage of trained laboratory technicians and hematologists who are proficient in the use of cutting-edge diagnostic technologies. To address this challenge, it is essential to invest in training and capacity building for healthcare workers across the continent. Programs that focus on training laboratory professionals in the use of molecular diagnostic tools, as well as providing ongoing education on the latest advancements in leukemia diagnostics, are critical to ensuring that these innovations are utilized effectively. International collaborations and partnerships with global health organizations such as the World Health

Organization (WHO) and research institutions can help establish training programs and workshops to equip healthcare workers with the necessary skills. Additionally, offering remote training and telemedicine support can bridge the gap for healthcare professionals in rural and underserved areas, where in-person training opportunities may be limited.⁷⁶

Financial Support and Sustainable Funding Models

The high costs associated with advanced diagnostic technologies can be a major barrier to widespread adoption, particularly in low-resource settings. Many African countries struggle with limited healthcare budgets, making it challenging to prioritize and invest in expensive diagnostic equipment. To expand access, there needs to be a coordinated effort between governments, international donors, non-governmental organizations, and the private sector to provide sustainable financial support for leukemia diagnostic innovations. Financial assistance can take various forms, including grants, subsidies, and affordable pricing models for diagnostic equipment. The World Health Organization (WHO), along with other international bodies, has an essential role in advocating for financial support and facilitating collaborations that bring down the costs of advanced diagnostic technologies. Additionally, leveraging public-private partnerships can help ensure that the financial burden of implementing these innovations is shared, making it easier for African healthcare systems to adopt and sustain advanced diagnostic tools. Moreover, developing sustainable funding models that focus on long-term support for diagnostic innovations is crucial. These models should consider not only the initial investment in equipment but also the ongoing costs related to maintenance, training, and reagents. Creating a reliable and affordable supply chain for diagnostic materials, as well as ensuring that healthcare facilities have the resources to maintain and repair equipment, will be key to making these innovations sustainable over the long term.⁷⁷

Mobile and Remote Diagnostic Solutions

Given the vast geographical landscape of Africa, with many communities in remote and hard-to-reach areas, mobile diagnostic solutions offer a promising way to extend the reach of advanced leukemia diagnostics. Mobile diagnostic units equipped with essential tools for leukemia diagnosis can travel to rural and underserved areas, providing timely testing and consultation services to communities that otherwise lack access to advanced healthcare. Incorporating telemedicine into the diagnostic process can further enhance access, allowing healthcare providers in remote areas to consult with specialists in urban centers. Remote diagnostics can enable the interpretation of complex test results and the development of treatment plans, ensuring that even patients in the most remote areas receive expert care. WHO and other international organizations can play a role in facilitating the implementation of these mobile diagnostic units and telemedicine platforms by providing technical support, funding, and training.⁷⁸

Regional Collaboration and Knowledge Sharing

Regional collaboration is an essential strategy for expanding access to leukemia diagnostic innovations across Africa. By fostering cooperation between African countries, healthcare institutions, and research centers, it becomes possible to share knowledge, resources, and best practices, ensuring that diagnostic innovations are more widely disseminated. Regional diagnostic networks can be established to connect countries with similar healthcare challenges, enabling the sharing of diagnostic tools, reagents, and expertise. These networks can also facilitate the exchange of data and research findings, contributing to a better understanding of leukemia trends in Africa and informing the development of more effective diagnostic strategies tailored to the continent's unique needs. Collaborative efforts among African countries can help build a collective approach to tackling the barriers to accessing advanced diagnostics, ensuring that progress in one region can benefit others.⁷⁹

Advocacy and Policy Development

Expanding access to diagnostic innovations also requires strong advocacy efforts to ensure that leukemia diagnosis is prioritized within national healthcare agendas. WHO, along with local governments and advocacy organizations, must work together to raise awareness about the importance of early leukemia diagnosis and the role of advanced diagnostic tools in improving patient outcomes. By developing and implementing national health policies that prioritize cancer diagnostics and integrate advanced diagnostic technologies into healthcare systems, African countries can build

sustainable frameworks for access to leukemia diagnostics. These policies should address the various barriers to access, including funding, infrastructure, and workforce challenges, while promoting the development of cancer care as a key component of national health strategies.

Chronic Lymphocytic Leukemia (CLL) Management in Africa

Chronic lymphocytic leukemia (CLL), the most common adult leukemia in high-income countries, presents unique challenges in Africa due to limited diagnostic resources, treatment availability, and healthcare infrastructure. Despite these challenges, progress is being made in selected regions, with WHO-supported initiatives, private-sector partnerships, and government interventions helping to improve CLL care.^{16,80–82}

Diagnosis

In African countries with well-developed healthcare systems, such as South Africa, Egypt, and Morocco, CLL diagnosis follows international standards. Flow cytometry, immunophenotyping, and molecular testing are routinely performed in tertiary centers to confirm CLL and assess prognostic markers such as TP53 mutations and IgHV status. Conversely, in resource-limited settings like Nigeria, Uganda, and Sudan, CLL is often diagnosed at an advanced stage due to the reliance on basic blood film examination and complete blood count (CBC) alone. Flow cytometry, which is essential for distinguishing CLL from other lymphoproliferative disorders, is often unavailable outside major cities. In rural areas, patients may not receive a definitive diagnosis, leading to mismanagement or treatment delays.

Treatment

In high-income African nations such as South Africa and Egypt, frontline therapies for CLL include chemoimmunotherapy (FCR – Fludarabine, Cyclophosphamide, and Rituximab) and targeted agents like ibrutinib (a Bruton's tyrosine kinase inhibitor, BTKi). These treatments have significantly improved survival rates. Some private and government-sponsored programs subsidize ibrutinib for eligible patients, making targeted therapy more accessible. However, in low-resource settings like Malawi, Ethiopia, and Burkina Faso, the cost of these drugs is prohibitive, and patients often receive chlorambucil monotherapy, an older, less effective chemotherapy regimen. Rituximab, a monoclonal antibody essential for combination therapy, is available in some referral hospitals but remains out of reach for many due to high costs. The WHO and global cancer initiatives have made efforts to negotiate reduced prices for rituximab, but accessibility remains a major challenge.

Monitoring and Supportive Care

Regular monitoring of CLL patients requires frequent CBC tests, lymphocyte counts, and periodic imaging, which is readily available in countries with better healthcare infrastructure, such as Morocco and Tunisia. Patients are monitored for disease progression, and treatment decisions are based on well-established guidelines. In contrast, in Mozambique and the Democratic Republic of the Congo, routine monitoring is sporadic. Patients often present with advanced disease due to a lack of awareness and limited access to hematologists. Opportunistic infections, a major concern in immunosuppressed CLL patients, are often inadequately managed due to shortages of broad-spectrum antibiotics and antifungal medications.

Palliative and Supportive Care

In many African nations, palliative care services are underdeveloped. However, in countries like Kenya and Ghana, non-governmental organizations (NGOs) have established leukemia support programs that provide pain management, nutritional support, and counseling for patients with advanced CLL. These programs help bridge the gap in healthcare access, but they are often limited to urban centers, leaving rural patients underserved.

Molecular Subdivisions in AML and ALL: Implications for Treatment and Future Improvements in Africa

Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are highly heterogeneous diseases, with molecular markers playing a crucial role in prognosis and treatment selection. In high-income countries, molecular profiling, including FLT3, NPM1, and IDH1/2 mutations in AML and BCR-ABL status in ALL, guides targeted therapy decisions, improving patient outcomes. However, in much of Africa, leukemia treatment still relies heavily on traditional chemotherapy due to limited access to molecular diagnostics and targeted therapies. By leveraging existing infrastructure for chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) management, African healthcare systems could improve AML and ALL care through enhanced diagnostic capacity, research collaborations, and treatment accessibility.^{83,84}

The Role of Molecular Subdivisions in AML and ALL Treatment

AML Subtypes and Targeted Therapies

- FLT3-mutated AML: Patients benefit from FLT3 inhibitors (midostaurin, gilteritinib) in combination with chemotherapy.
- NPM1-mutated AML: NPM1 mutations often indicate a favorable prognosis, but co-mutations (eg, FLT3) influence treatment decisions.
- IDH1/2-mutated AML: IDH inhibitors (ivosidenib, enasidenib) provide new options for patients with these mutations.
- Current African Reality: In countries like South Africa and Egypt, some tertiary centers offer FLT3 testing, guiding targeted therapy. However, in most other African nations, AML treatment remains limited to standard chemotherapy (cytarabine + anthracycline) without molecular stratification.

ALL Subtypes and Targeted Therapies

- BCR-ABL+ (Philadelphia chromosome-positive) ALL: Requires tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or ponatinib alongside chemotherapy.
- BCR-ABL-negative ALL: Standard chemotherapy remains the primary treatment, with additional risk-based stratifications.
- Current African Reality: BCR-ABL testing is available in selected centers in South Africa, Nigeria, and Kenya, but remains largely inaccessible in rural regions, leading to delays in initiating TKI therapy.

Leveraging Existing CML and CLL Infrastructure for AML/ALL Care

African healthcare systems have made progress in molecular testing and targeted therapy for CML and CLL, particularly through:

- BCR-ABL testing infrastructure for CML, which can be expanded to test for Philadelphia chromosome-positive ALL.
- Flow cytometry labs established for CLL diagnosis, which can be adapted for AML and ALL immunophenotyping.
- Existing access programs for TKIs in CML, which could be extended to BCR-ABL+ ALL.

However, AML and ALL require additional molecular testing (FLT3, NPM1, IDH1/2), which remains largely unavailable outside of South Africa and Egypt. Many African countries still rely on clinical diagnosis and morphology alone, leading to suboptimal treatment strategies.

Strategies to Improve AML and ALL Diagnosis and Treatment in Africa

Expand Molecular Testing Networks

Establish regional reference laboratories capable of FLT3, NPM1, IDH1/2, and BCR-ABL testing. Leverage existing PCR-based testing for BCR-ABL in CML to include ALL patients. Invest in next-generation sequencing (NGS) technology in major teaching hospitals to improve AML/ALL classification.

Improve Access to Targeted Therapies

Integrate FLT3 inhibitors into existing national leukemia treatment programs. Expand WHO-supported access programs for TKIs (imatinib, dasatinib) to include Philadelphia-positive ALL. Encourage generic drug production to reduce costs of novel AML/ALL therapies.

Enhance Training of Hematologists and Laboratory Scientists

Provide specialized training on AML/ALL molecular testing in African medical schools and hospitals. Promote partnerships between African healthcare systems and global leukemia research institutions.

Develop Regional Treatment Guidelines

Establish African-specific leukemia treatment protocols, integrating available therapies and diagnostic capabilities. Encourage multinational collaborations to develop cost-effective treatment approaches tailored to African healthcare systems.

Challenges in Leukemia Care Delivery in Africa: Barriers and Potential Solutions

Leukemia, a complex group of hematologic malignancies, presents a significant challenge to healthcare systems worldwide. In Africa, the burden of leukemia is compounded by numerous barriers that hinder early diagnosis, effective treatment, and long-term management. These challenges stem from limited healthcare infrastructure, inadequate diagnostic capacity, high treatment costs, and insufficient specialized workforce. Addressing these gaps requires a multi-faceted approach that includes improving diagnostic facilities, expanding access to targeted therapies, enhancing healthcare policies, and fostering international collaborations.^{85,86}

The Challenge of Early Diagnosis and Molecular Testing

Leukemia care begins with accurate and timely diagnosis, yet in many African nations, this remains a significant hurdle. In well-resourced countries, leukemia is classified based on molecular and cytogenetic markers, allowing for personalized treatment strategies. In Africa, however, the lack of diagnostic facilities limits access to essential tests such as flow cytometry, polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS).⁸⁷

For example:

- Chronic myeloid leukemia (CML) requires BCR-ABL testing, yet many hospitals in Africa rely solely on complete blood counts (CBC) and blood smear microscopy, leading to misdiagnosis or delayed treatment.
- Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) demand molecular profiling for mutations like FLT3, NPM1, and IDH1/2 in AML and BCR-ABL status in ALL, yet most hospitals outside major cities lack the capacity for these advanced tests.

Potential Solutions

- Establishment of regional molecular diagnostic hubs: Centralized reference laboratories equipped with advanced testing capabilities can serve multiple hospitals within a country or across borders.
- Public-private partnerships to subsidize leukemia diagnostics: Government support, in collaboration with NGOs and pharmaceutical companies, can make molecular testing more accessible.
- Training programs for laboratory scientists: Expanding the workforce with expertise in leukemia diagnostics can improve the accuracy and efficiency of testing (Figure 1).

Limited Access to Standard and Targeted Therapies

Treatment disparities are among the most pressing concerns in leukemia care in Africa. Many countries lack access to modern therapies, relying on outdated chemotherapy regimens.




Figure 1 Disparities in Leukemia Diagnosis in Africa.

- For CML, tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib have revolutionized survival outcomes. However, high drug costs and erratic supply chains make these therapies inaccessible in many African nations. Some initiatives, such as the Max Foundation's free imatinib program, have improved access, but gaps remain.
- For AML and ALL, targeted therapies such as FLT3 inhibitors, IDH inhibitors, and monoclonal antibodies (rituximab, blinatumomab, and inotuzumab) are standard in high-income countries but remain largely unavailable in African settings due to cost and regulatory hurdles.
- Bone marrow transplantation (BMT), a curative option for certain leukemias, is limited to a handful of countries such as South Africa, Egypt, and Morocco, making it inaccessible to the vast majority of patients.

Potential Solutions

- Negotiation of lower drug prices: Governments and health organizations should collaborate with pharmaceutical companies to subsidize leukemia medications and include them in national insurance programs.
- Expansion of local drug manufacturing: Producing generic versions of leukemia drugs within Africa could reduce costs and improve supply chains.
- Development of regional bone marrow transplant centers: Encouraging the establishment of transplant units in key regions could improve access to curative treatment (Figure 2).

Lack of Specialized Healthcare Professionals

A severe shortage of hematologists, oncologists, and trained oncology nurses further complicates leukemia care in Africa. Many countries have only a handful of specialists, with most practicing in urban areas. Rural and underserved regions often rely on general practitioners who may have limited experience in managing leukemia.

Potential Solutions

- Expansion of medical training programs: Increasing hematology and oncology fellowship positions in African universities and medical institutions can build a larger workforce.
- International exchange programs: Collaborations with global institutions can provide African doctors with specialized training in leukemia care.
- Telemedicine and remote consultation networks: Leveraging technology to connect local physicians with international leukemia experts can improve patient management in remote areas (Figure 3).




Figure 2 Comparing Accessibility Challenges in Leukemia Therapies.




Figure 3 Addressing the Shortage of Leukemia Care Specialists in Africa.

Financial Barriers and Lack of Universal Healthcare Coverage

Leukemia treatment is expensive, and in many African countries, patients must pay out of pocket, leading to high rates of treatment abandonment. Even when therapies are available, high costs of hospitalization, laboratory tests, and supportive care place a heavy financial burden on families.

Potential Solutions

- Inclusion of leukemia treatment in national health insurance programs: Governments should expand insurance schemes to cover leukemia care, ensuring that patients are not forced to abandon treatment due to financial constraints.
- International funding and donation programs: Establishing leukemia-specific funds can help provide financial aid to patients in need.

Challenges in Long-Term Follow-Up and Supportive Care

Leukemia requires lifelong monitoring and supportive care, but many African healthcare systems lack structured follow-up programs.

- CML patients on TKIs require regular BCR-ABL monitoring, yet access to PCR testing is limited.
- AML and ALL survivors face risks of relapse, but in many areas, post-treatment surveillance is inconsistent.
- Supportive care, including blood transfusions, antibiotics, and antifungal medications, is often inadequate, leading to high infection-related mortality.

Potential Solutions

- Implementation of structured follow-up programs: Establishing electronic health records and tracking systems can improve continuity of care.
- Investment in local blood banking and transfusion services: Strengthening these services will ensure that leukemia patients receive adequate supportive care.
- Expansion of community-based leukemia awareness programs: Educating patients and caregivers about long-term management can improve adherence to treatment and follow-up.

Recommendations and Country-Specific Instances of WHO-Supported Innovations in Leukemia Diagnosis and Treatment

To strengthen leukemia diagnosis and treatment in Africa, the following recommendations should be implemented based on existing WHO-supported laboratory innovations and country-specific successes:

Strengthen Diagnostic Capacity Across All Healthcare Levels

In South Africa, leukemia diagnosis is well-supported with advanced technologies such as flow cytometry, cytogenetics, and molecular testing (BCR-ABL PCR for CML diagnosis). Patients have access to comprehensive leukemia workups, including bone marrow aspiration and targeted therapy monitoring. In contrast, in Malawi and Chad, resource limitations restrict diagnostic tools to basic blood film analysis and full blood count (FBC), making it difficult to differentiate leukemia subtypes, particularly chronic myeloid leukemia (CML). WHO should expand the availability of affordable diagnostic tools, such as point-of-care PCR and digital pathology, in low-resource settings.

Improve Accessibility to Molecular Testing for CML (BCR-ABL Testing and Monitoring)

- Nigeria and Kenya: In major urban centers such as Lagos and Nairobi, some referral hospitals offer BCR-ABL testing, allowing accurate diagnosis of CML. However, access is often limited to private healthcare facilities, making it costly for many patients.
- Uganda and Ethiopia: In many public hospitals, CML diagnosis relies on clinical symptoms and blood film analysis without molecular confirmation, leading to diagnostic delays and mismanagement.
- Recommendation: WHO should support the expansion of centralized reference laboratories that offer subsidized or free BCR-ABL testing and monitoring for CML patients under national leukemia programs.

Establish Government-Funded Leukemia Treatment Programs for Equitable Access

Morocco has implemented a government-subsidized leukemia treatment program where CML patients receive imatinib through a state-sponsored initiative, significantly improving survival rates. In Senegal, lack of funding and high drug costs mean that many CML patients rely on NGOs or self-financing for treatment, leading to therapy discontinuation. More African countries should establish government-funded leukemia treatment programs, with WHO facilitating cost-sharing agreements with pharmaceutical companies for sustainable drug access.

Expand Public-Private Partnerships to Improve Access to Targeted Therapy

Egypt has successfully partnered with international organizations and pharmaceutical companies to provide affordable tyrosine kinase inhibitors (TKIs) for CML patients, ensuring continuity of care. In contrast, in Sudan and the Democratic Republic of the Congo, CML patients often rely on intermittent donations of TKIs, leading to inconsistent therapy and poor outcomes. WHO should encourage partnerships between African governments, private pharmaceutical firms, and international donors to ensure the sustained availability of leukemia medications.

Enhance Training and Retention of Hematologists and Laboratory Personnel

In Ghana, WHO-supported training programs have helped increase the number of hematologists in tertiary hospitals, leading to better leukemia management. However, in BurkinaFaso, the lack of trained specialists forces many leukemia patients to seek treatment abroad, adding financial burdens. WHO should scale up its hematology training initiatives by offering scholarships and continuous professional development courses to retain skilled personnel in Africa.

Establish Leukemia Surveillance and Data Collection Systems

South Africa has a well-developed cancer registry that tracks leukemia cases, treatment outcomes, and mortality rates, guiding policy decisions. However, in Tanzania and Mozambique, there are no comprehensive leukemia registries, making it difficult to assess disease prevalence and treatment effectiveness. WHO should work with national ministries of health to establish and fund leukemia surveillance systems to improve data-driven decision-making in resource-limited countries.

Strengthen Regional Collaboration for Leukemia Research and Treatment Protocols

Rwanda and Uganda have collaborated on cross-border leukemia treatment research, allowing resource-sharing between their national health programs. In contrast, many West African nations lack inter-country collaboration, leading to fragmented care models. WHO should support regional initiatives where countries can pool resources and expertise to advance leukemia care through shared research and training programs.

Conclusion

Expanding access to leukemia diagnostic innovations in Africa is a vital step toward improving health outcomes and reducing mortality rates associated with the disease. Despite the progress made in developing advanced diagnostic technologies, challenges such as inadequate healthcare infrastructure, limited resources, and a shortage of trained professionals continue to hinder the widespread implementation of these innovations. However, through concerted efforts and strategic investments, significant strides can be made to ensure that all regions of Africa, including underserved areas, have access to timely and accurate leukemia diagnosis. The potential to overcome these challenges lies in a multifaceted approach that focuses on enhancing healthcare infrastructure, building capacity among local healthcare workers, and securing sustainable financial support. Decentralizing diagnostic services and introducing mobile solutions can help bridge the geographic gaps that prevent access to advanced diagnostic tools. Furthermore, regional collaborations and knowledge sharing are essential in maximizing the collective resources and expertise available across the continent. These initiatives, combined with advocacy and strong policy frameworks, can ensure that innovations are not only accessible but also sustainable in the long term.

Abbreviations

CML, chronic myelogenous leukemia; MRD, minimal residual disease; NGS, next-generation sequencing; PCR, polymerase chain reaction; WHO, World Health Organization.

Disclosure

The author reports no conflicts of interest in this work.

References

1. Vernooij E, Kelly A, Rogers J, Gbetuwa M, Street A. *Laboratory Strengthening in Public Health Emergencies: Perspectives From Sierra Leone*. Edinburgh, United Kingdom: University of Edinburgh; 2020.
2. Obeagu EI, Obeagu GU. The nexus between obesity and leukemia progression in HIV-positive individuals: a review. *Elite J Haematol*. 2024;2(4):180–198.
3. Obeagu EI, Omar DM, Omar U. Leukaemia burden in Africa. *Int J Curr Res Biol Med*. 2023;1:17–22.
4. Obeagu EI, Obeagu GU. The impact of body mass index (BMI) on immune function in leukemia patients living with HIV: a review. *Elite J Immunol*. 2024;2(4):73–92.

5. Obeagu EI, Obeagu GU. The impact of obesity on overall survival in leukemia patients living with HIV: a review. *Elite J Labor Med.* 2024;2(4):26–45.
6. World Health Organization. World report on knowledge for better health: strengthening health systems. World Health Organization; 2004.
7. World Health Organization. WHO global strategy on people-centred and integrated health services: interim report. World Health Organization; 2015.
8. World Health Organization. A vision for primary health care in the 21st century: towards universal health coverage and the Sustainable Development Goals. World Health Organization; 2018.
9. World Health Organization Maximizing Positive Synergies Collaborative Group. An assessment of interactions between global health initiatives and country health systems. *Lancet.* 2009;373(9681):2137–2169. doi:10.1016/S0140-6736(09)60919-3
10. Kohlmann A, Bacher U, Schnittger S, Haferlach T. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing. *Leukemia Lymphoma.* 2014;55(8):1725–1734. doi:10.3109/10428194.2013.856427
11. Black JS, Salto-Tellez M, Mills KI, Catherwood MA. The impact of next generation sequencing technologies on haematological research—a review. *Pathogenesis.* 2015;2(1–2):9–16. doi:10.1016/j.pathog.2015.05.004
12. Morganti S, Tarantino P, Ferraro E, et al. Complexity of genome sequencing and reporting: next generation sequencing (NGS) technologies and implementation of precision medicine in real life. *Crit rev oncol/hematol.* 2019;133:171–182. doi:10.1016/j.critrevonc.2018.11.008
13. Brown M, Wittwer C. Flow cytometry: principles and clinical applications in hematology. *Clin Chem.* 2000;46(8):1221–1229. doi:10.1093/clinchem/46.8.1221
14. Musaigwa F. *Investigating the use of standardized EuroFlow flow cytometry panels for the characterisation and diagnosis of Chronic lymphocytic leukaemia in the Tygerberg Academic Hospital, South Africa* (Doctoral dissertation, Stellenbosch: Stellenbosch University). 2017.
15. Miranda-Filho A, Piñeros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F. Epidemiological patterns of leukaemia in 184 countries: a population-based study. *Lancet Haematol.* 2018;5(1):e14–24. doi:10.1016/S2352-3026(17)30232-6
16. Musaigwa F, Grewal R, Abayomi A, Swanepoel CC. Chronic lymphocytic leukaemia trends and features at a tertiary hospital in South Africa (2011–2016). *South African J Oncol.* 2021;5:168.
17. Opie J, Antel K, Koller A, Novitzky N. In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes. *Ann Hematol.* 2020;99:571–578. doi:10.1007/s00277-020-03908-8
18. Wilson S, Steele S, Adeli K. Innovative technological advancements in laboratory medicine: predicting the lab of the future. *Biotechnol. Biotechnol. Equip.* 2022;36(sup1):S9–21. doi:10.1080/13102818.2021.2011413
19. Salah HT, Muhsen IN, Salama ME, Owaidah T, Hashmi SK. Machine learning applications in the diagnosis of leukemia: current trends and future directions. *Int J Labor Hematol.* 2019;41(6):717–725. doi:10.1111/ijlh.13089
20. Haferlach T, Kohlmann A, Wiczorek L, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the international microarray innovations in Leukemia study group. *J clin oncol.* 2010;28(15):2529–2537. doi:10.1200/JCO.2009.23.4732
21. Mason J, Griffiths M. Molecular diagnosis of leukemia. *Expert Review of Molecular Diagnostics.* 2012;12(5):511–526. doi:10.1586/erm.12.44
22. watt CD, Bagg A. Molecular diagnosis of acute myeloid leukemia. *Expert Review of Molecular Diagnostics.* 2010;10(8):993–1012. doi:10.1586/erm.10.85
23. Al-Dewik NI, Qoronfleh MW. Genomics and precision medicine: molecular diagnostics innovations shaping the future of healthcare in Qatar. *Adv Public Health.* 2019;2019(1):3807032. doi:10.1155/2019/3807032
24. Peters JM, Ansari MQ. Multiparameter flow cytometry in the diagnosis and management of acute leukemia. *Arch Pathol Lab Med.* 2011;135(1):44–54. doi:10.5858/2010-0387-RAR.1
25. Weir EG, Borowitz MJ. Flow cytometry in the diagnosis of acute leukemia. *Semin hematol.* 2001;38(2):124–138. doi:10.1016/S0037-1963(01)90046-0
26. Van Dongen JJ, Orfao A. EuroFlow: resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine. *Leukemia.* 2012;26(9):1899–1907. doi:10.1038/leu.2012.121
27. Grimwade LF, Fuller KA, Erber WN. Applications of imaging flow cytometry in the diagnostic assessment of acute leukaemia. *Methods.* 2017;112:39–45. doi:10.1016/j.ymeth.2016.06.023
28. Akkari YM, Baughn LB, Dubuc AM, et al. Guiding the global evolution of cytogenetic testing for hematologic malignancies. *Blood J Am Soc Hematol.* 2022;139(15):2273–2284.
29. Béné MC, Grimwade D, Haferlach C, Haferlach T, Zini G, European LeukemiaNet. Leukemia diagnosis: today and tomorrow. *Eur J Haematol.* 2015;95(4):365–373. doi:10.1111/ejh.12603
30. Mack EK, Marquardt A, Langer D, et al. Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing. *Haematologica.* 2018;104(2):277.
31. Duncavage EJ, Schroeder MC, O’Laughlin M, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. *N Engl J Med.* 2021;384(10):924–935. doi:10.1056/NEJMoa2024534
32. Zhong Y, Xu F, Wu J, Schubert J, Li MM. Application of next generation sequencing in laboratory medicine. *Ann Lab Med.* 2021;41(1):25–43. doi:10.3343/alm.2021.41.1.25
33. Bacher U, Shumilov E, Flach J, et al. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. *Blood Cancer J.* 2018;8(11):113. doi:10.1038/s41408-018-0148-6
34. Serrati S, De Summa S, Pilato B, et al. Next-generation sequencing: advances and applications in cancer diagnosis. *Oncotargets Ther.* 2016;7355–7365. doi:10.2147/OTT.S99807
35. Luthra R, Patel KP, Reddy NG, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. *Haematologica.* 2014;99(3):465. doi:10.3324/haematol.2013.093765
36. Al-Worafi YM. Laboratory Medicine Practice in Developing Countries. In: *Handbook of Medical and Health Sciences in Developing Countries: Education, Practice, and Research.* Cham: Springer International Publishing; 2024:1–24.
37. Sayed S, Cherniak W, Lawler M, et al. Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions. *Lancet.* 2018;391(10133):1939–1952. doi:10.1016/S0140-6736(18)30459-8

38. Parsons LM, Somoskövi Á, Gutierrez C, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. *Clin Microbiol Rev*. 2011;24(2):314–350. doi:10.1128/CMR.00059-10
39. Scheffler RW. Managing the future: the Special Virus Leukemia Program and the acceleration of biomedical research. *Stud History Philosophy Sci C*. 2014;48:231–249. doi:10.1016/j.shpsc.2014.09.005
40. Church DL, Naugler C. Using a systematic approach to strategic innovation in laboratory medicine to bring about change. *Critical Rev Clinl Labor Sci*. 2022;59(3):178–202. doi:10.1080/10408363.2021.1997899
41. Plehani M. Advancing value-based laboratory medicine. *Clini ChemLabor Med (CCLM)*. 2025;63(2):249–257. doi:10.1515/cclm-2024-0823
42. Li F, Wang H, Ye T, et al. Recent advances in material technology for leukemia treatments. *Adv Mater*. 2024;36(26):2313955. doi:10.1002/adma.202313955
43. Eckardt JN, Bornhäuser M, Wendt K, Middeke JM. Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects. *Blood Adv*. 2020;4(23):6077–6085. doi:10.1182/bloodadvances.2020002997
44. Samson EO, Adamu I, Mba I, Emmanuel A, Amarachi BJ, Musa M. Diagnostic approach to haematologic malignancies in resource-limited settings-A review. *Sokoto J Med Lab Sci*. 2024;9(2):22–27. doi:10.4314/sokjmls.v9i2.3
45. Leak SA, Mmbaga LG, Mkwizu EW, Mapendo PJ, Henke O. Hematological malignancies in East Africa—Which cancers to expect and how to provide services. *PLoS One*. 2020;15(5):e0232848. doi:10.1371/journal.pone.0232848
46. Gopal S, Wood WA, Lee SJ, et al. Meeting the challenge of hematologic malignancies in sub-Saharan Africa. *Blood. J Am Soc Hematol*. 2012;119(22):5078–5087.
47. Meillon-Garcia LA, Demichelis-Gomez R. Access to therapy for acute myeloid leukemia in the developing world: barriers and solutions. *Curr Oncol Rep*. 2020;22:1. doi:10.1007/s11912-020-00987-8
48. Gopal S, Wood WA, Lee SJ, et al. Meeting the challenge of hematologic malignancies in sub-Saharan Africa. *Blood J Am Soc Hematol*. 2012;119(22):5078–5087.
49. Adebamowo CA, Casper C, Bhatia K, et al. Challenges in the detection, prevention, and treatment of HIV-associated malignancies in low-and middle-income countries in Africa. *J Acquir Immune Defic Syndr*. 2014;67:S17–26.
50. Chirande LF, Namazzi R, Hockenberry M, et al. Building capacity for pediatric hematological diseases in Sub-Saharan Africa. *Blood Adv*. 2024;2024:bloodadvances-2024012983.
51. Pearlman PC, Divi R, Gwede M, et al. The national institutes of health affordable cancer technologies program: improving access to resource-appropriate technologies for cancer detection, diagnosis, monitoring, and treatment in low-and middle-income countries. *IEEE J Translational Engi Health Med*. 2016;4:1–8.
52. Thokerunga E, Ntege C, Ahmed AO. Are African primary physicians suspicious enough? Challenges of multiple myeloma diagnosis in Africa. *Egyptian J Inter Med*. 2021;33(1):54. doi:10.1186/s43162-021-00088-3
53. Lubega J, Chirande L, Atwine B, et al. Addressing the childhood cancer crisis in sub-Saharan Africa. *Lancet Oncol*. 2023;24(7):729–732. doi:10.1016/S1470-2045(23)00173-0
54. Adachi T, El-Hattab AW, Jain R, et al. Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges. *Int J Environ Res Public Health*. 2023;20(6):4732. doi:10.3390/ijerph20064732
55. Al Lamki Z. Improving cancer care for children in the developing world: challenges and strategies. *Curr Pediatric Rev*. 2017;13(1):13–23. doi:10.2174/1573396312666161230145417
56. Van Heerden J, Lisa Christine I, Downing J, et al. Current status of African pediatric oncology education efforts aligned with the Global Initiative for Childhood Cancer. *Pediatric Hematol Oncol*. 2023;40(3):224–241. doi:10.1080/08880018.2022.2117882
57. Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. *Transfusion Med Rev*. 2012;26(2):164–180. doi:10.1016/j.tmr.2011.07.006
58. Tapela NM, Mpunga T, Hedt-Gauthier B, et al. Pursuing equity in cancer care: implementation, challenges and preliminary findings of a public cancer referral center in rural Rwanda. *BMC Cancer*. 2016;16:1–9. doi:10.1186/s12885-016-2256-7
59. Naresh KN, Raphael M, Ayers L, et al. Lymphomas in sub-Saharan Africa—what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research? *Br J Haematol*. 2011;154(6):696–703. doi:10.1111/j.1365-2141.2011.08772.x
60. Schneidman M, Matu M, Nkengasong J, Githui W, Kalyesubula-Kibuuka S, Silva KA. Building cross-country networks for laboratory capacity and improvement. *Clin Lab Med*. 2018;38(1):119–130. doi:10.1016/j.cll.2017.10.009
61. Adewole I, Martin DN, Williams MJ, et al. Building capacity for sustainable research programmes for cancer in Africa. *Nat Rev Clin Oncol*. 2014;11(5):251–259. doi:10.1038/nrclinonc.2014.37
62. Desai D, Wu G, Zaman MH. Tackling HIV through robust diagnostics in the developing world: current status and future opportunities. *Lab on a Chip*. 2011;11(2):194–211. doi:10.1039/C0LC00340A
63. Orozco JD, Greenberg LA, Desai IK, et al. Building laboratory capacity to strengthen health systems: the partners in health experience. *Clinics Lab Med*. 2018;38(1):101–117. doi:10.1016/j.cll.2017.10.008
64. Njukeng PA, Njumkeng C, Ntongowa C, Abdulaziz M. Strengthening laboratory networks in the Central Africa region: a milestone for epidemic preparedness and response. *Afr J Lab Med*. 2022;11(1):1–5. doi:10.4102/ajlm.v11i1.1492
65. McNerney R, Peeling RW. Regulatory in vitro diagnostics landscape in Africa: update on regional activities. *Clinl Infect Dis*. 2015;61(suppl_3):S135–140. doi:10.1093/cid/civ553
66. Pritchard-Jones K, Pieters R, Reaman GH, et al. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. *Lancet Oncol*. 2013;14(3):e95–103. doi:10.1016/S1470-2045(13)70010-X
67. Ribeiro RC, Howard SC. Access Determines Outcomes for People with Acute Lymphoblastic Leukemia in Low-and Middle-Income Countries. In: *Acute Lymphoblastic Leukemia in Children and Adolescents*. Cham: Springer Nature Switzerland; 2024:345–361.
68. Akingbola A, Adegbesan A, Ojo O, Otumara JU, Alao UH. Artificial intelligence and cancer care in Africa. *J Med Surg Public Health*. 2024;3:100132. doi:10.1016/j.glmedi.2024.100132
69. Thomford NE, Dzobo K, Chimusa E, et al. Personalized herbal medicine? A roadmap for convergence of herbal and precision medicine biomarker innovations. *OMICS*. 2018;22(6):375–391. doi:10.1089/omi.2018.0074
70. Ceppi F, Antillon F, Pacheco C, et al. Supportive medical care for children with acute lymphoblastic leukemia in low-and middle-income countries. *Exp Rev Hematol*. 2015;8(5):613–626. doi:10.1586/17474086.2015.1049594

71. Tekinturhan E, Audureau E, Tavalacci MP, Garcia-Gonzalez P, Ladner J, Saba J. Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program. *BMC Health Serv Res.* 2013;13:1–9. doi:10.1186/1472-6963-13-304
72. Dzobo K. What to Do for Increasing Cancer Burden on the African Continent? Accelerating public health diagnostics innovation for prevention and early intervention on cancers. *OMICS.* 2021;25(9):567–579. doi:10.1089/omi.2021.0098
73. Wal P, Saed A, Almahtout AM, Ahmed SA. A multidisciplinary exploration of diseases, treatments, and impact, from cancer-related anemia to pandemics and therapeutics. *Libyan J Med Applied Sci.* 2023;2023:14–30.
74. Molyneux E, Scanlan T, Chagaluka G, Renner L. Haematological cancers in African children: progress and challenges. *Br J Haematol.* 2017;177(6):971–978. doi:10.1111/bjh.14617
75. Lin LL, Lakomy DS, Chiao EY, et al. Clinical trials for treatment and prevention of HIV-associated malignancies in sub-Saharan Africa: building capacity and overcoming barriers. *JCO Global Oncol.* 2020;6:1134–1146. doi:10.1200/GO.20.00153
76. Stulac S, Binagwaho A, Tapela NM, et al. Capacity building for oncology programmes in sub-Saharan Africa: the Rwanda experience. *Lancet Oncol.* 2015;16(8):e405–413. doi:10.1016/S1470-2045(15)00161-8
77. Atun R, Knaul FM. Innovative financing: local and global opportunities. *Closing Canc Divide.* 2012;2012:257–288.
78. Razzano D, Puranam K, Tomoka T, Fedoriv Y. The role of telepathology in improving cancer diagnostic and research capacity in sub-Saharan Africa. *Front Med.* 2022;9:978245. doi:10.3389/fmed.2022.978245
79. Hill JA, Kimani K, White A, et al; Daisy's Eye Cancer Fund & The Kenyan National Retinoblastoma Strategy Group. Achieving optimal cancer outcomes in East Africa through multidisciplinary partnership: a case study of the Kenyan National Retinoblastoma Strategy group. *Globalization Health.* 2016;12:1. doi:10.1186/s12992-016-0160-1
80. Obeagu EI, Omar DE, Bunu UO, Obeagu GU, Alum EU, Ugwu OP. Leukaemia burden in Africa. *Int J Curr Res Biol Med.* 2023;1:17–22.
81. Yang S, Varghese AM, Sood N, et al. Ethnic and geographic diversity of chronic lymphocytic leukaemia. *Leukemia.* 2021;35(2):433–439. doi:10.1038/s41375-020-01057-5
82. Chiatton CS, Gabus R, Pavlovsky MA, Akinola NO, Varghese AM, Arrais-Rodrigues C. Management of CHRONIC LYMPHOCYTIC LEUKEMIA IN LESS-RESOURCED countries. *Cancer J.* 2021;27(4):314–319. doi:10.1097/PPO.0000000000000533
83. Iyer P. Pediatric AML: state of the Art and Future Directions. *Pediatric Hematol Oncol.* 2025;2025:1–20.
84. Okello CD, Niyonzima N, Ferrareso M, et al. Haematological malignancies in sub-Saharan Africa: east Africa as an example for improving care. *Lancet Haematol.* 2021;8(10):e756–769. doi:10.1016/S2352-3026(21)00198-8
85. Woudberg R, Sinanovic E. Priority setting for improved leukemia management and research in South Africa: a modified Delphi study. *Cancer Causes Control.* 2025;2025:1–3.
86. Hashmi SK, Geara F, Mansour A, Aljurf M. Cancer management at sites with limited resources: challenges and potential solutions. *Comprehensive Cancer Center.* 2022;2022:173–185.
87. Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. *Lancet.* 2010;376(9747):1186–1193. doi:10.1016/S0140-6736(10)61152-X

Blood and Lymphatic Cancer: Targets and Therapy

Publish your work in this journal

Blood and Lymphatic Cancer: Targets and Therapy is an international, peer-reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/blood-and-lymphatic-cancer-targets-and-therapy-journal>

Dovepress
Taylor & Francis Group